FDA Grants Priority Review To Roche’S Inavolisib For Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer ...
(MENAFN- GlobeNewsWire - Nasdaq) Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options 1,2 Additional analyses of INAVO120 will be presented in an oral abstract session …